MYND Life Sciences (MYND) Ratios
MYND Life Sciences Ratios
TSE:MYND's free cash flow for Q3 2024 was $53.00. For the 2024 fiscal year, TSE:MYND's free cash flow was increased by $1.31K and operating cash flow was $-1.25K. See a summary of the company’s cash flow.
| Ratios | Jan 24 | Jan 23 | Jan 22 | Oct 20 | Oct 19 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.14 | 0.06 | 5.76 | 0.00 | 0.00 |
| Quick Ratio | 0.14 | 0.06 | 5.76 | 0.00 | 0.00 |
| Cash Ratio | 0.00 | 0.00 | 5.35 | 0.00 | 0.00 |
| Solvency Ratio | -0.26 | -0.84 | -1.56 | 0.00 | 0.00 |
| Operating Cash Flow Ratio | -0.03 | -0.44 | -8.41 | -0.05 | -0.39 |
| Short-Term Operating Cash Flow Coverage | -0.07 | -0.73 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ -4.98M | $ -3.95M | $ -696.31K | $ -53.69K | $ -1.83K |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 3.76 | 3.95 | 0.87 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | -0.60 | -0.73 | -34.18 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | -1.52 | -2.73 | 1.03 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 1.04 | 0.00 | 0.00 |
| Financial Leverage Ratio | -0.16 | -0.19 | -39.29 | -0.00 | 0.00 |
| Debt Service Coverage Ratio | -0.49 | -0.90 | -29.93 | 0.00 | 0.00 |
| Interest Coverage Ratio | -2.48 | -4.62 | -31.82 | 0.00 | 0.00 |
| Debt to Market Cap | 4.23 | 0.66 | 0.05 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.08 | 0.07 | 0.05 | 0.00 | 0.00 |
| Net Debt to EBITDA | -1.64 | -0.87 | -0.10 | 0.00 | 0.00 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 96.49% | 96.29% | 100.00% | 100.00% |
| EBT Per EBIT | 83.96% | 120.70% | 105.68% | 100.00% | 100.00% |
| Return on Assets (ROA) | -190.32% | -545.36% | -163.54% | -80665.71% | 0.00% |
| Return on Equity (ROE) | 30.50% | 100.99% | 6425.37% | 105.31% | 138.75% |
| Return on Capital Employed (ROCE) | 36.32% | 88.21% | -185.33% | 105.31% | 138.75% |
| Return on Invested Capital (ROIC) | 91.43% | 312.47% | -173.25% | 105.31% | 138.75% |
| Return on Tangible Assets | -190.32% | -545.36% | -163.54% | 0.00% | 0.00% |
| Earnings Yield | -214.07% | -95.53% | -10.01% | -0.09% | -0.07% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.30 | 0.08 | 0.41 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | -2104940244586463232.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1200.27 | -4335.80 | -898.86 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | -0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 1200.27 | 4335.80 | 898.86 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | -0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.00 | -0.04 | -0.07 | -0.00 | -0.00 |
| Free Cash Flow Per Share | -0.00 | -0.04 | -0.07 | -0.00 | -0.00 |
| Dividend Paid and CapEx Coverage Ratio | -49564.00 | 0.00 | -19.96 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | -49564.00 | 0.00 | -19.96 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | -0.07 | -0.70 | -1.28 | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -27.96% | -48.72% | -7.18% | -0.00% | -0.02% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.47 | -1.05 | -9.99 | -1075.00 | -1446.06 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | -0.14 | -1.06 | -641.60 | -1132.10 | -2006.43 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -3.58 | -2.05 | -13.92 | -21850.59 | -5177.61 |
| Price-to-Operating Cash Flow Ratio | -3.58 | -2.05 | -14.62 | -21850.59 | -5177.61 |
| Price-to-Earnings Growth (PEG) Ratio | 0.01 | 0.05 | -0.00 | -32.25 | 0.00 |
| Enterprise Value Multiple | -2.03 | -2.12 | -10.47 | 0.00 | 0.00 |
| Enterprise Value | 3.71M | 6.32M | 44.03M | 60.70M | 3.67M |
| EV to EBITDA | -2.03 | -2.12 | -10.47 | 0.00 | 0.00 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -18.71 | -3.47 | -14.06 | -21850.59 | -5177.61 |
| EV to Operating Cash Flow | -18.71 | -3.47 | -14.76 | -21850.59 | -5177.61 |
| Tangible Book Value Per Share | -0.11 | -0.08 | -0.00 | -0.00 | -0.00 |
| Shareholders’ Equity Per Share | -0.11 | -0.08 | -0.00 | -0.00 | -0.00 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.04 | 0.04 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.03 | -0.08 | -0.10 | -0.00 | -0.00 |
| Tax Burden | 1.00 | 0.96 | 0.96 | 1.00 | 1.00 |
| Interest Burden | 0.83 | 1.22 | 1.06 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.13 | 0.51 | 0.68 | 0.05 | 0.28 |
Currency in CAD